Business, energy, technology, markets and global industry news from Business News Today

Sichuan Kelun-Biotech Biopharmaceutical Co.

PharmaDeviceNews Sichuan Kelun-Biotech Biopharmaceutical Co.
Kelun-Biotech’s investigational dual-payload antibody-drug conjugate SKB565 advances toward Phase 1/2 clinical testing for advanced solid tumors following a China clinical trial notice. Representative image.
Pharma & Biotech

SKB565 clinical trial: Why Kelun-Biotech’s first dual-payload ADC matters

Kelun-Biotech’s SKB565 gains China clinical trial clearance, moving its first dual-payload ADC toward a Phase 1/2 solid-tumor study.

Read More
Kelun-Biotech’s sacituzumab tirumotecan plus pembrolizumab met the Phase III PFS endpoint in first-line PD-L1-negative non-squamous NSCLC. Representative image.
Pharma & Biotech

Why Kelun-Biotech’s latest sac-TMT Phase III result could matter more than the headline suggests

Kelun-Biotech reports improved Phase III PFS with sac-TMT plus pembrolizumab, while survival and detailed safety data remain pending.

Read More
Representative image of oncology researchers reviewing lung cancer imaging and genomic data, reflecting Kelun-Biotech’s lunbotinib fumarate Phase II results in RET fusion-positive non-small cell lung cancer.
Pharma & Biotech

Kelun-Biotech’s ASCO 2026 data strengthens China’s next wave of targeted cancer drugs

Kelun-Biotech’s RET lung cancer data looks strong, but CNS durability and global competition will decide its real impact.

Read More
Representative image of a lung cancer treatment setting, as OptiTROP-Lung05 data put sacituzumab tirumotecan at the centre of the first-line NSCLC immunotherapy debate.
Pharma & Biotech

Can TROP2 ADCs reshape first-line NSCLC after Kelun-Biotech’s OptiTROP-Lung05 win?

A TROP2 ADC just pushed past pembrolizumab alone in first-line lung cancer. See why OptiTROP-Lung05 matters now.

Read More
Representative image: Advanced lung cancer research and oncology treatment planning are becoming central to the debate over whether Kelun-Biotech’s sacituzumab tirumotecan and pembrolizumab combination can reshape first-line NSCLC care.
Pharma & Biotech

Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market

ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.

Read More